会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 103. 发明申请
    • CIS/TRANS RIBOREGULATORS
    • CIS / TRANS RIBOREGULATORS
    • WO2004046321A3
    • 2005-02-03
    • PCT/US0336506
    • 2003-11-14
    • UNIV BOSTONCOLLINS JAMES JISAACS FARREN JDWYER DANIEL JCANTOR CHARLES R
    • COLLINS JAMES JISAACS FARREN JDWYER DANIEL JCANTOR CHARLES R
    • C12N15/11C12N15/67C12Q1/68C07H21/04A01K67/00
    • C12N15/67C12N15/11C12N2310/53C12Q1/6897
    • The present invention provides nucleic acid molecules, DNA constructs, plasmids, and methods for post-transcriptional regulation of gene expression using RNA molecules to both repress and activate translation of an open reading frame. Repression of gene expression is achieved through the presence of a regulatory nucleic acid element (the cis-repressive RNA or crRNA) within the 5' untranslated region (5' UTR) of an mRNA molecule. The nucleic acid element forms a hairpin (stem/loop) structure through complementary base pairing. The hairpin blocks access to the mRNA transcript by the ribosome, thereby preventing translation. In particular, in embodiments of the invention designed to operate in prokaryotic cells, the stem of the hairpin secondary structure sequesters the ribosome binding site (RBS). In embodiments of the invention designed to operate in eukaryotic cells, the stem of the hairpin is positioned upstream of the start codon, anywhere within the 5' UTR of an mRNA. A small RNA (trans-activating RNA, or taRNA), expressed in trans, interacts with the crRNA and alters the hairpin structure. This alteration allows the ribosome to gain access to the region of the transcript upstream of the start codon, thereby activating transcription from its previously repressed state.
    • 本发明提供核酸分子,DNA构建体,质粒和用于转录后调节基因表达的方法,其使用RNA分子抑制和激活开放阅读框的翻译。 通过在mRNA分子的5'非翻译区(5'UTR)内存在调节性核酸元件(顺式抑制性RNA或crRNA)来实现基因表达的抑制。 核酸元件通过互补碱基配对形成发夹(茎/环)结构。 发夹阻止核糖体进入mRNA转录物,从而阻止翻译。 特别地,在设计用于在原核细胞中操作的本发明的实施方案中,发夹二级结构的茎螯合核糖体结合位点(RBS)。 在设计用于在真核细胞中操作的本发明的实施方案中,发夹的茎位于起始密码子的上游,位于mRNA的5'UTR内的任何位置。 以反式表达的小RNA(反式激活RNA或taRNA)与crRNA相互作用并改变发夹结构。 这种改变允许核糖体进入起始密码子上游的转录物区域,从而从其先前的抑制状态激活转录。
    • 108. 发明申请
    • METHODS OF TREATING CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE WITH AICAR, (5-AMINO-4-IMIDAZOLE CARBOXAMIDE RIBOSIDE) AND RELATED COMPOUNDS
    • 治疗与胰岛素抗药性相关的病症的方法(5-氨基-4-咪唑烷酰胺酰胺)及相关化合物
    • WO0209726A9
    • 2003-09-12
    • PCT/US0124194
    • 2001-07-31
    • UNIV BOSTONGARVAN INSTRUDERMAN NEILKRAEGEN EDWARD WIDO YASUO
    • RUDERMAN NEILKRAEGEN EDWARD WIDO YASUO
    • A61K31/00A61K31/7056C12Q1/48A61K31/70
    • C12Q1/485A61K31/00A61K31/7056
    • The long-term usage of AICAR (5-amino, 4-imidazole carboxamide riboside) to produce sustained metabolic and biological changes in mammals that overcome insulin resistance, i.e., increase insulin sensitivity, and result in benefits in diseases and conditions such as diabetes, hypertension, atherosclerosis, polycystic ovary syndrome and gallstones is described. Long-term usage of AICAR, particularly intermittent administration, e.g., three days per week, appears to have some of the positive offects of exercise, having an impact on the amount of food consumed by a subject and resulting in reduced fat build-up and increase in muscle mass. Therefore, AICAR administration has a positive impact in reducing obesity. AICAR can also prove useful in preventing or treating vascular diseases associated with hyperglycemia, high plasma levels of free fatty acids (FFA)and triglyceride, and insulin resistance by virtue of the fact that this agent activates fatty acid oxidation. Animal tests have shown that chronic intermittent treatment with AICAR has not resulted in any noticeable toxic effects. AICAR and related compounds are activators of AMP-activated protein kinase (AMPK) and, furthermore, are effective at decreasing malonyl CoA levels in the animal.
    • AICAR(5-氨基,4-咪唑甲酰胺核苷)长期使用可以克服胰岛素抵抗的哺乳动物产生持续的代谢和生物学变化,即增加胰岛素敏感性,并导致疾病和病症如糖尿病, 描述了高血压,动脉粥样硬化,多囊卵巢综合征和胆结石。 AICAR的长期使用,特别是间歇性给药,例如每周三天,似乎具有一些积极的运动成分,对受试者消耗的食物量产生影响,并导致脂肪堆积减少, 肌肉量增加 因此,AICAR管理对减少肥胖有积极的影响。 AICAR也可用于预防或治疗与高血糖,游离脂肪酸(FFA)和甘油三酸酯的高血浆水平以及胰岛素抵抗相关的血管疾病,这是因为该药物能够激活脂肪酸氧化。 动物实验表明,AICAR慢性间歇性治疗并未产生明显的毒性作用。 AICAR和相关化合物是AMP活化蛋白激酶(AMPK)的活化剂,此外,在降低动物中丙二酰辅酶A水平方面是有效的。